New Arrivals
| Chemical Structure | Cat. No. | Product Name | CAS No. |
|---|
 |
BCP46317 | Samrotamab New | 2052591-32-7 |
Samrotamab is a biosimilar that targets LRRC15.
|
|||
 |
BCP46316 | Enapotamab New | 1912423-61-0 |
Enapotamab is an Anti-AXL Antibody.
|
|||
 |
BCP46315 | Tepoditamab New | 2044679-53-8 |
Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds CLEC12A on myeloid cells and CD3ε on cytotoxic T cells.
|
|||
 |
BCP46314 | Mitazalimab New | 2055640-86-1 |
Mitazalimab is an agonistic – or stimulatory – antibody that targets CD40, a receptor in the dendritic cells of the immune system, which are the cells that detect enemies such as cancer cells.
|
|||
 |
BCP46313 | Onvatilimab New | 1969313-51-6 |
Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody.
|
|||
 |
BCP46310 | Cetrelimab New | 2050478-92-5 |
Cetrelimab (JNJ-63723283) is a monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor
|
|||
 |
BCP46309 | Imaprelimab New | 2014343-04-3 |
Imaprelimab (PRX-003) is an anti-MCAM mAb developed as a novel therapy for psoriasis
|
|||
 |
BCP46308 | Leronlimab New | 674782-26-4 |
Leronlimab, a CCR5-specific humanised IgG4 monoclonal antibody originally developed for the treatment of HIV has been studied for the treatment of COVID-19.
|
|||
 |
BCP46307 | Ravagalimab New | 2050816-56-1 |
Ravagalimab is a potent CD40 antibody.
|
|||
 |
BCP46306 | Lenvervimab New | 2055006-79-4 |
Lenvervimab is a monoclonal anti-HBsAg antibody.
|
|||
 |
BCP46305 | Abrezekimab New | 2043952-59-4 |
Abrezekimab (UCB4144) is an anti-IL-13 agent that is in development as an anti-asthmatic agent.
|
|||
 |
BCP46304 | Etigilimab New | 2044984-83-8 |
Etigilimab is a human-derived monoclonal antibody. Etigilimab targets TIGIT.
|
|||
 |
BCP46303 | Sutimlimab New | 2049079-64-1 |
Sutimlimab, a humanized monoclonal antibody, selectively targets the C1s protein, a C1 complex serine protease responsible for activating this pathway.
|
|||
 |
BCP46302 | Vopratelimab New | 2039148-04-2 |
Vopratelimab is an IgG1 ICOS antibody.
|
|||
 |
BCP46301 | Bersanlimab New | 1987854-08-9 |
Bersanlimab is a biosimilar that targets ICAM1.
|
|||
 |
BCP46300 | Iscalimab New | 2031153-61-2 |
Iscalimab is a fully human, CD40 pathway blocking, nondepleting monoclonal antibody.
|
|||
 |
BCP46299 | Cibisatamab New | 1855925-27-7 |
Cibisatamab (CEA-TCB) is a T cell bispecific antibody.
|
|||
 |
BCP46297 | 6-Chloropurine -9-beta-D-(3',5'-di-O-benzoyl-2'-deoxy-2'-fluoro)arabinoriboside New | 135473-15-3 |
 |
BCP46295 | GSK2256294A New | 1142090-23-0 |
GSK2256294A is a potent and selective sEH inhibitor, which is in investigation in patients with endothelial dysfunction or abnormal tissue repair, such as diabetes, wound healing or COPD. GSK2256294 exhibited potent cell-based activity, a concentration-dependent inhibition of the conversion of 14,15-EET to 14,15-DHET in human, rat and mouse whole blood in vitro, and a dose-dependent increase in the LTX/LTX diol ratio in rat plasma following oral administration.
|
|||
 |
BCP46296 | MNK1/2-IN-5 New | 1426928-20-2 |
MNK1/2-IN-5 is a potent and selective MNK1/2 inhibitor as a therapeutic agent.
|
|||
